US › Healthcare

Entrada Therapeutics Inc (TRDA)

US · Healthcare · Biotechnology

$4.37-8.58%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$898,000

Revenue YoY

-53.9%

Net profit

$-42.8M

EPS

$-1.01

EPS estimate

$-1.16

Net margin

-4,762.0%

EPS came in at -1.01 against a street estimate of -1.16 — a beat of 12.9%.

Key statistics

Market cap

$186.1M

Forward P/E

3,333.3

P/B

1.12

Book value

$6.47

EPS (TTM)

$-3.96

52-week high

$16.45

52-week low

$4.11

50-day MA

$6.68

200-day MA

$9.11

Beta

-0.24

Analyst view

Analysts rate Entrada Therapeutics Inc a strong buy (7 buy, 1 hold, 0 sell out of 8) with an average price target of $19.00.

Shareholding

Insiders

12.23%

Institutions

82.11%

Largest institutional holders

Fund	Stake
Baker Bros Advisors LP	13.03%
5AM Venture Management, LLC	10.42%
BlackRock Inc	6.63%
Merck & Co Inc	4.47%
Vanguard Capital Management, LLC	3.26%
MPM Oncology Impact Management LP	3.22%
TCG Crossover Management, LLC	2.72%
Wellington Management Company LLP	2.45%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Entrada Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.